Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenyl biguanide is a small molecule biguanide derivative primarily utilized in pharmacological research as a selective agonist for the 5-hydroxytryptamine receptor 3 (5-HT3). While structurally related to anti-diabetic biguanides like metformin and phenformin, phenyl biguanide exhibits distinct pharmacokinetic and pharmacodynamic properties, notably poor mitochondrial uptake. In oncology research, it has been investigated for its potential effects on cancer cell metabolism and growth; however, studies indicate it has minimal growth inhibitory effects on bladder and colon cancer cell lines compared to other biguanides. It is most commonly employed as a tool to study 5-HT3-mediated physiological responses, such as the Bezold-Jarisch reflex, in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenyl biguanide.